Skip to content
nCage Therapeutics
A scientist at a stereo microscope in a laboratory, working in protective gear.

Pipeline

Best-in-class vaccines, built on one platform

Protein cages are synthetic virus-like particles that display biological material on their surface, or carry molecules such as nucleic acids or proteins into the cell. Our cages are programmable, which gives them significant potential as both drug delivery systems and vaccines.

Leading candidates

Lyme Disease Vaccine

Stage of development
Design of VLP
Rationale for market entry
  • There is currently no vaccine for Lyme disease
  • A growing problem in the US and Western Europe
  • The disease carries long-term complications
More about Lyme disease
Phase start
2025
Partner
Jagiellonian UniversityJagiellonian University

Universal Flu Vaccine

Stage of development
Challenge animal experiments
Rationale for market entry
  • Elderly patients are recommended to have both Covid and flu boosters
  • No combination option is available
More about influenza
Phase start
2024
Partner
University of Oxford

Other pipeline assets

RSV Vaccine

Stage of development
Design of VLP
Rationale for market entry
  • RSV is a leading cause of severe respiratory illness in infants and older adults, and options for protecting patients remain limited
More about RSV
Phase start
2023
Partner
National Institutes of Health
University of Nottingham

Drug Delivery System

Stage of development
Design of VLP
Rationale for market entry
  • Programmable protein cages can carry nucleic acids or proteins into cells, opening a route to therapies that are hard to deliver today
More about drug delivery systems
Phase start
2024
Partner
Ryvu Therapeutics